Telix Pharmaceuticals has rebounded strongly, reaching profitability and guiding FY2026 revenue to $

Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares moved upwards by 74.6% to $0.75 during Friday&#3

Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperfor

GuidanceFY 2026 revenue and other income are expected to be in excess of US$1 billion, with revenue

Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript

Telix Pharmaceuticals NASDAQ: TLX reported first-half 2026 revenue of $477 million, up 22% from the

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limit

MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limit

Telix is evolving into a vertically integrated radiopharmaceutical platform, leveraging diagnostics,

MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limit

The average of price targets set by Wall Street analysts indicates a potential upside of 86.2% in Te

Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET

MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limi

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limit

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announced that the first

MELBOURNE (Australia) and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limi

MELBOURNE, Australia and INDIANAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limit

Citigroup analyst Laura Sutcliffe maintains Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and low

HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a

Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperfor

MELBOURNE, Australia and INDIANAPOLIS, July 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals (ASX:

Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeu

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limit

Partnership to evaluate Telix's innovative precision medicine products and candidates in combina

MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceu

MELBOURNE, Australia and INDIANAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limit

MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limite

Telix Pharmaceuticals Limited offers a potent mix of derisking, downside cushion, and accelerating c

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the IPAX-

MELBOURNE, Australia and INDIANAPOLIS, May 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limite

Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free

Telix to partner with companies developing advanced minimally invasive and image-guided ablative tec

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the publicatio

MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limi

US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnin

Telix collaborates with Regeneron, targeting radiopharmaceutical development, with milestones up to

Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperfor

HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a

Collaboration is a 50/50 cost and profit-sharing model and combines Telix's expertise in radioph

FDA accepts Telix NDA for Pixclara for brain cancer imaging, analysts see confidence rebuild amid st

Telix Pharma stock climbs on strong Q1 growth and Phase 3 study success. Analysts maintain Buy ratin

Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperfor

HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a

Telix Pharma's ProstACT study achieves primary objectives, positioning TLX591-Tx as potential fi

Key findings include:Tolerability profile supported by dosimetry and low-grade non-hematologic event

Citigroup analyst Laura Sutcliffe maintains Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and rai

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that it has su

Telix Pharmaceuticals meets its FY25 revenue target with strong Q4 growth, expanded U.S. launches an